ArticleBiomolecules & biomedicine2026
Prognostic nomogram for overall survival in breast invasive micropapillary carcinoma integrating LODDS and treatment factors: A SEER-based study.
Article in Biomolecules & biomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Invasive micropapillary carcinoma (IMPC) of the breast is a rare and aggressive histologic subtype characterized by frequent lymph node metastasis and poor prognosis. The conventional American Joint Committee on Cancer (AJCC) tumor-node-metastasis (TNM) staging system does not account for treatment modalities or advanced nodal metrics such as the log odds of positive lymph nodes (LODDS), which may limit prognostic accuracy. This study aimed to develop and internally validate a nomogram integrating clinicopathologic characteristics, treatment variables, and LODDS to predict overall survival (OS) in breast IMPC. Clinicopathologic and survival data from 1,105 patients diagnosed between 2010 and 2015 were obtained from the Surveillance, Epidemiology, and End Results (SEER) database. The entire cohort was used for model development, with bootstrap resampling for internal validation. Least absolute shrinkage and selection operator (LASSO) regression and multivariable Cox analysis were used for variable selection and nomogram construction. Model performance was assessed using the optimism-corrected concordance index (C-index), calibration plots, time-dependent area under the receiver operating characteristic curve (AUC), decision curve analysis (DCA), and clinical impact curves (CICs), while incremental value over the AJCC TNM system was evaluated by net reclassification improvement (NRI) and integrated discrimination improvement (IDI). Ten prognostic factors were retained in the nomogram: age, tumor size, LODDS, marital status, tumor grade, M stage, rural/urban residence, molecular subtype, radiotherapy, and chemotherapy. The nomogram showed superior discrimination to TNM staging, with better optimism-corrected C-index and 3-, 5-, and 10-year AUCs (all p < 0.05), significant improvements in NRI and IDI (all p < 0.001), excellent calibration, and greater net clinical benefit on DCA and CICs. Exploratory risk stratification identified high- and low-risk groups with significantly different survival outcomes (log-rank p < 0.001). This nomogram may improve prognostic assessment in breast IMPC, although the risk stratification remains exploratory and requires external validation before clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.